Merck leans into AI with $610M in biobucks for Absci drug discovery pactnews2022-01-07T15:38:42+00:00January 7th, 2022|FierceBiotech|
Atea sticks it out with failed COVID-19 antiviral but also raids Merck’s store room for hepatitis C drugnews2022-01-07T15:02:01+00:00January 7th, 2022|FierceBiotech|
Cytokinetics finds worldwide partner in Royalty Pharma for heart failure drug, snags up to $450M to extend runwaynews2022-01-07T14:11:39+00:00January 7th, 2022|FierceBiotech|
AstraZeneca picks up new weapon in rare disease fight with Alnylam and Pfizer, paying $30M for rights to an early-phase assetnews2022-01-07T12:35:36+00:00January 7th, 2022|FierceBiotech|
Chutes & Ladders—Maraganore’s post-Alnylam ambitions take flightnews2022-01-06T19:53:52+00:00January 6th, 2022|FierceBiotech|
Aligos says stop right now to lead hep B med after fruitless phase 1 datanews2022-01-06T19:49:01+00:00January 6th, 2022|FierceBiotech|
Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientianews2022-01-06T16:51:56+00:00January 6th, 2022|FierceBiotech|
Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugsnews2022-01-06T14:19:19+00:00January 6th, 2022|FierceBiotech|
Sanofi tears up Sangamo cell therapy deal in pivot to off-the-shelf approachesnews2022-01-06T13:08:56+00:00January 6th, 2022|FierceBiotech|
Novartis taps Alnylam for ambitious push to fix liver functionnews2022-01-06T12:29:22+00:00January 6th, 2022|FierceBiotech|
